1. Food and Drug Administration, Center for Drug Evaluation and Research (2003) Guidance for industry: bioavailability and bioequivalence studies for orally administered drug products—general considerations. Revision 1. http://www.fda.gov/downloads/Drugs/GuidanceComplianceRegulatoryInformation/Guidances/ucm070124.pdf Accessed 10 October 2014
2. European Medicines Agency, Committee for Medicinal Products for Human Use (2010) Guideline on the investigation of bioequivalence. CPMP/EWP/QWP/1401/98 Rev. 1. http://www.ema.europa.eu/docs/en_GB/document_library/Scientific_guideline/2010/01/WC500070039.pdf Accessed 10 October 2014
3. Schuirmann DJ(1987) A comparison of the Two One-Sided Test Procedure and the Power Approach for assessing equivalence of average bioavailability. J Pharmacokin Biopharm 15:657–660
4. McGilveray IJ, Midha KK, Skelly JP, Dighe S, Doluisio JT, French IW, Karim A, Burford R (1990) Consensus report from “Bio International ’89”: issues in the evaluation of bioavailability data. J Pharm Sci 79:945–946. doi: 10.1002/jps.2600791022
5. Melander H (1992) Problems and possibilities with the add-on subject design. In: Midha KK, Blume HH (eds) Bio-International. Bioavailability, bioequivalence and pharmacokinetics. medpharm, Stuttgart, pp 85–90